Amneal Wins FDA Approval for Romidepsin Injection, Securing 180-Day Exclusivity
AMRX sits 84% above its 52-week low of $7.07.
Summary
Amneal Pharmaceuticals announced FDA approval for its romidepsin injection solution, an oncology medicine. This approval grants the company 180 days of market exclusivity, targeting a market that saw approximately $78 million in sales for the prior formulation. The ready-to-use solution offers operational advantages for hospitals and strengthens Amneal's growing injectables business. This positive development follows recent strong Q1 earnings and the strategic acquisition of Kashiv BioSciences.
At the time of this announcement, AMRX was trading at $12.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $7.07 to $15.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.